Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PEGASYS · 3 trials · 4 indications
Stable virological response is serum Hepatitis B virus deoxyribonucleic acid (HBV DNA) \<20 000 copies/ml during the treatment (after each 12 weeks) and after the follow-up period (24 weeks after the last treatment period).
| Arm | Type | Description |
|---|---|---|
| PEGASYS | EXPERIMENTAL | Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously. |
| Aspirin | ACTIVE_COMPARATOR | 81 or 100 mg daily. |
| No Intervention | NO_INTERVENTION | Participants were on non- specific anti-viral treatment. |
| Name | Type | Description |
|---|---|---|
| PEGASYS | DRUG | - |
| Aspirin | DRUG | 81 or 100 mg daily. |
| PEGASYS [peginterferon alfa-2a] | DRUG | There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment. |
Inclusion Criteria: * Clinical diagnosis of hepatitis B * Not pregnant Exclusion Criteria: * Treatment for hepatitis B in past 6 months * Other hepatitis infections * Severe liver disease * Pregnancy
PEGASYS (peginterferon alfa-2a) is used for chronic hepatitis B, including HBeAg-negative chronic hepatitis B, and for high-risk polycythemia vera. It is an investigational small molecule in Phase 3 development for these indications.
PEGASYS is a pegylated form of interferon alfa-2a, a cytokine that modulates the immune response. It works by binding to interferon receptors on cell surfaces, activating signaling pathways that enhance antiviral and antiproliferative activities, thereby helping to control viral replication and abnormal cell growth.
PEGASYS is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the pharmaceutical company responsible for the clinical development and commercialization of this drug.
PEGASYS is in Phase 3 clinical development for chronic hepatitis B. It is not FDA approved and remains investigational. Clinical trials have been completed for chronic hepatitis B and other conditions, but the drug is still under study.
PEGASYS has been studied in clinical trials including NCT00048945, a Phase 3 study in chronic hepatitis B with 820 participants, and NCT00442572, a Phase 2 study in HBeAg-negative chronic hepatitis B. These trials are completed.
Yes, PEGASYS is the brand name for peginterferon alfa-2a (40KD). The drug is a pegylated interferon alfa-2a molecule, and the terms are used interchangeably in clinical research and medical literature.